Previous 10 | Next 10 |
Summary Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD. This week no picks beat 10% gains in less than a week with SLCR peak at +7.1% and continuing the highest negative Mom...
Truist has initiated Fusion Pharmaceuticals ( NASDAQ: FUSN ) at buy citing the potential of the company's lead candidate, FPI-1434, currently in phase 1 for solid tumors. The firm has a $10 price target (~217% upside based on Thursday's close). Analyst Nicole Germino s...
Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference Canada NewsWire HAMILTON, ON and BOSTON , Sept. 7, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on ...
Fusion Pharmaceuticals ( NASDAQ: FUSN ) said on Monday the first patient had been dosed in the Phase 1/2 study testing FPI-1966 in patients with advanced solid tumors. The study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer targe...
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3 Canada NewsWire HAMILTON, ON and BOSTON , Aug. 29, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a ...
Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q2 GAAP EPS of -$0.44 beats by $0.09 . Revenue of $0.57M (+9.6% Y/Y) beats by $0.46M . For further details see: Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0....
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates Canada NewsWire FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule-based targeted alpha therapy Data supporting ongoing evaluatio...
Fusion Pharmaceuticals ( NASDAQ: FUSN ) stock gained as much as 10.6% to $2.72 in Wednesday trading, after William Blair research initiated the clinical-stage oncology company with an outperform rating. William Blair analyst Andy Hsieh, "using conservative parameters and...
The clinical-stage oncology company Fusion Pharmaceuticals ( NASDAQ: FUSN ) announced on Thursday that the FDA cleared its Investigational New Drug (IND) applications for [225Ac]-FPI-2059 and the corresponding imaging analogue [111In]-FPI-2058. FPI-2059 is a small molecule...
Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1 Canada NewsWire HAMILTON, ON and BOSTON , June 23, 2022 /CNW/ -- Fusion Pharmaceuti...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...